Collectively, this study reveals the crucial role of PRMT5 blockade combined with CPT‐11 in inducing a mismatch repair deficiency‐like state and provides a novel triple‐drug combination therapy strategy as a potential treatment for patients with MSS CRC. This evidence concerns the gene PRMT5 and colorectal carcinoma.